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transcription and integration. This latter property is considered to be essential for productive replication and ensures the stable long-
term insertion of the viral genome sequence in the host chromatin, thereby leading to the life-long association of the virus with the
infected cell. Using HIV as a prototypic example, the present review aims to provide an overview of how and where integration occurs,
as well as presenting general consequences for both the virus and the infected host.
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E-mail: Angela.Ciufﬁ@chuv.chIntroductionRetroviruses are enveloped RNA viruses, containing two copies
of single-stranded, non-segmented, positive RNA as genome. Like
all retroviruses, the human immunodeﬁciency virus type 1 (HIV-
1, abbreviated as HIV throughout the text) encodes three major
open reading frames: (i) gag, coding for the internal structural
proteins, which in the case of HIV are matrix (MA, p17), capsid
(CA, p24), nucleocapsid (NC, p7) and p6; (ii) pol, coding for the
virus enzymes, which are reverse transcriptase (RT, p66/p51),
integrase (IN, p32) and protease (PR, p11); and (ii) env, coding for
the envelope external structural proteins, which are the surface
glycoprotein (SU, gp120) and the transmembrane glycoprotein
(TM, gp41) forHIV (Fig. 1a). Moreover, HIV-1 encodes regulatory
and accessory genes— tat, rev, vif, vpr, vpu and nef—and is
therefore considered to be a complex retrovirus.
In order to establish a productive replication, HIV needs ﬁrst
to deliver its genome-containing viral core to the cytoplasm of
the infected cell (Fig. 1b). Subsequently, the viral RNA genomeMicrobiol Infect 2016; 22: 324–332
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hence the name, retrovirus. The viral DNA genome is com-
plexed with the viral integrase enzyme (also referred to as the
intasome), as well as with additional viral and cellular proteins in
a ribonucleoprotein complex called the pre-integration com-
plex (PIC). The exact PIC composition is still controversial but
additional proteins may include the viral proteins RT, MA, Vpr
and CA, as well as the cellular proteins lens-epithelium derived
growth factor (LEDGF/p75), barrier-to-autointegration factor
(BAF) and high-mobility group AT-hook 1 (HMGA1) (reviewed
in ref. [1]). Components of PIC are necessary for the successful
nuclear import and ﬁnal stable insertion of the viral genome in
the host DNA. As discussed below, these two steps have been
shown to impact integration efﬁciency and site location, and are
essential to ensure the life-long persistence of the provirus in
the infected cell.How? Mechanism of IntegrationThe viral integrase enzyme is the only protein determinant
required to successfully join and so insert a DNA fragment into
a heterologous target DNA sequence (reviewed in refs [2,3]).
The prototypical HIV-1 IN is a 288-amino-acid protein, and
is divided into three major domains: an N-terminal domain, a
catalytic core domain and a C-terminal domain (Fig. 2a)European Society of Clinical Microbiology and Infectious Diseases
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FIG. 1.Overview of the human immunodeﬁciency virus type 1 (HIV-1) genome organization and replication cycle. (a) HIV genome contains nine open
reading frames (ORF), coding for 15 proteins. The proviral genome is ﬂanked by direct long-terminal repeats (LTR) that contain all transcriptional
regulatory sequences. The pol ORF encodes the three viral enzymes necessary for replication that are protease (PR), reverse transcriptase (RT) and
integrase (IN). (b) The HIV replication cycle can be divided into seven steps: (1) HIV binds to its target cell through the interaction of gp120 to the cell
CD4 molecule, which is mostly expressed at the surface of lymphoid and myeloid cells. This ﬁrst interaction allows the subsequent binding of gp120
with a chemokine receptor, CCR5 or CXCR4, followed by the fusion between the viral membrane and the cellular membrane triggered by gp41. This
ensures the release of the viral core in the cytoplasm of the host cell. (2) The viral core disassembles (uncoating process) and the viral RNA genome is
reverse transcribed in a linear double-stranded DNA copy through the action of the viral reverse transcriptase enzyme, giving rise to the pre-
integration complex (PIC). (3) The PIC, minimally containing the viral DNA (vDNA) genome and the viral IN enzyme, is translocated to the nu-
cleus through the nuclear pore. This nuclear import step requires multiple interactions between viral and cellular proteins, including capsid (CA)
binding to nuclear pore proteins (NUPs). (4) Once in the nucleus, the viral IN catalyses the stable insertion of the viral DNA genome into the host
chromatin, tethered mainly by the cellular lens-epithelium derived growth factor (LEDGF)/p75 protein. LTR circles, 1-LTR and 2-LTR circles, are
considered as dead-end by-products produced by the cellular DNA repair machinery, the homology repair (HR) or non-homologous end-joining
(NHEJ) pathway, respectively. (5) Once integrated, the provirus is transcribed by the cellular RNA polymerase II machinery as most cellular coding
genes. Viral transcripts (with different levels of splicing) are exported from the nucleus to the cytoplasm where they are translated (6). (7) Two copies
of full-length (unspliced) viral RNA and viral proteins assemble, thereby producing new particles that are released from the cellular membrane. Finally,
the viral protease cleaves viral polyproteins leading to mature and infectious viral particles.
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FIG. 2. Mechanism of viral integration. (a)
Domain organization of the human immuno-
deﬁciency virus type 1 (HIV-1) integrase
enzyme, common to all retroviral integrases.
Indicated residues constitute motifs that are
conserved throughout integrases. (b) Details
of the integration reaction. The integration
reaction can be divided in three steps: (i) the
30 processing or terminal cleavage reaction,
(ii) the strand transfer reaction or DNA
joining reaction, and (iii) the DNA repair. The
ﬁrst two steps are carried out by the viral
integrase, whereas the last one is thought to
be performed by host cellular enzymes. The
intasome or stable synaptic complex (SSC)
contains viral DNA ends (red; red circles
mark the 50 end of viral DNA), each bound to
an integrase (IN) dimer (blue ovoids) that
multimerize, thereby resulting in a tetramer of
IN. The viral DNA attachment (att) sites
contain minimally 16 bp, including the
invariant CANN 3’-terminus, essential for
efﬁcient IN binding, processing and subse-
quent integration in target DNA. First, the IN
dimer removes a dinucleotide (GT) on each 30
viral DNA end, leaving an hydroxyl group on
the A nucleotide of the conserved CA
sequence (bold), and resulting in the cleaved
intasome or cleaved donor complex (CDC).
The second step occurs in the nucleus as IN
from the CDC has to bind to the host target
DNA (black), thereby forming the target
capture complex (TCC). A one-step trans-
esteriﬁcation reaction is carried out by the
viral IN, catalysing the simultaneous breaking
of the target DNA 5 bp apart and the covalent
joining of the 30-OH recessed viral DNA end,
thereby leading to the strand transfer com-
plex (STC). Of note, the 5-bp stagger in the
target DNA varies between 4 and 6 bp
depending on the retroviral IN (4 bp for
gammaretroviruses and spumaviruses, 5 bp
for lentiviruses and 6 bp for alpha-, beta- and
deltaretroviruses). Finally, enzymes of the
host DNA repair machinery remove the 50
protruding viral DNA ends (50-AC) and repair
the unpaired 5-base gap ﬂanking both ends of
the inserted viral DNA sequence, resulting in
the duplication of the 5-bp stagger on each
side of the viral sequence, and leading to the
stable integration of the viral DNA genome
(provirus) in the host target DNA.
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CMI Ciufﬁ The beneﬁts of integration 327(reviewed in refs [2,3]). The N-terminal domain contains a zinc-
binding HHCC motif, and is involved in IN multimerization and
viral DNA binding. The catalytic core domain contains the D,D-
35-E triad motif, which constitutes the catalytic active site
essential to coordinate a pair of Mg2+ ions and carry out the IN
enzymatic function. This motif is typical of polynucleotidyl
transferases, including retrotransposon integrases, bacterial
transposases and RAG1/2 recombinases [2]. The catalytic core
domain also contains key residues involved in target and viral
DNA binding. Finally, the C-terminal domain is mostly involved
in IN multimerization and DNA binding. Of note, some
retroviral integrases (including primate foamy virus, the spu-
maretrovirus prototype that provided most of the structural
information to date) display an additional domain of ~50 amino
acids called the N-terminal extension domain [4].
Successful viral integration occurs in three major steps,
which are the 30 processing reaction, the strand transfer re-
action and the DNA repair (Fig. 2b).Where? Integration Site SelectionIn vitro, IN is sufﬁcient to promote insertion of a donor DNA
into a target DNA, at any phosphodiester bond. However,
in vivo, retroviral integration is not random but rather favours
chromosomal features in a retrovirus-speciﬁc manner
(reviewed in refs [1,5–8]). This suggests that additional proteins
may play a role in integration, impacting both integration efﬁ-
ciency and integration site selection [6,9].
Upon the publication of the human genome, pioneering
studies using HIV and murine leukaemia virus (MLV, a gam-
maretrovirus) revealed speciﬁc retroviral genomic locations that
were preferentially selected for viral integration [10,11]. Since
then, multiple studies further investigated these insertion pref-
erences and this for most retroviral genera (reviewed in refs
[1,3,6–8,12]). It is now well established that HIV, and other
lentiviruses, favour active transcription units (i.e. genes for which
high amounts of corresponding transcripts were detected) that
are located in gene-dense regions, thereby correlating with high
GC content, high Alu elements, low LINE elements, light Giemsa
bands (so less condensed chromatin), and epigenetic marks of
active transcription (H3K4me, H3K4me2, H3K9me, H3K27me,
H3K36me, DNaseI hypersensitive sites and acetylated histones)
[6–8]. Lentiviruses favour integration throughout the tran-
scription units rather than promoter regions or transcription
start sites (Fig. 3, red arrows in the inset). In contrast, MLV
favours 50 ends of genes, i.e. close to transcription start sites, as
well as strong promoters and active enhancer regions, typically
marked by H3K4me1 and H3K27ac (Fig. 3, black arrows in the
inset) [13,14]. Other retroviral genera display alternativeClinical Microbiology and Infection © 2016 The Authors. Published by Elsevier Ltd on behalf
This is an open access artiintegration site distributions, with milder preferences for tran-
scription units or transcription start sites [7,8]. Of note, no
speciﬁc integration site preference for betaretroviruses (with
the mouse mammary tumour virus prototype) has been
revealed, so far making them unique among retroviruses because
they show a random integration site pattern.
In the past decade, these integration preferences have been
shown to be due to both nuclear import and tethering mech-
anisms (recently reviewed in [12]). To integrate in the host
chromatin, the pre-integration complex has ﬁrst to enter the
nucleus [15]. MLV PIC succeeds in reaching the host genome
only during cell mitosis, that is, when the nuclear membrane is
disrupted, and requires the viral p12 protein [12]. In contrast,
HIV can also infect non-dividing cells because HIV PIC can
interact with the nuclear import machinery to be actively
translocated through the nuclear membrane into the nucleus.
This ﬁrst difference in accessing the host genome also suggests
that the chromatin landscape encountered by the retroviral PIC
is different at the moment of tethering.
The ﬁrst hint of a link between nuclear import and integration
site selection was the observation that knock-down of TNPO3/
transportin-3, RanBP2/NUP358 and NUP153, all involved in
nuclear import, could bias integration preferences to regions
with lower gene density (Fig. 3) [16–20]. Since then, additional
nuclear pore proteins were shown to impact integration,
including CPSF6, Tpr and NUP98 [17,19,21–25]. Finally, Marini
et al. investigated the nuclear architecture and showed that the
open chromatin landscape in the vicinity of the nuclear pore
complex guided at ﬁrst HIV integration site preferences [26].
Indeed, chromatin is differentially distributed within the nucleus,
with condensed heterochromatin at the nuclear envelope and
more open chromatin within the nucleus [27]. Genes that are
actively transcribed tend to be located close to the nuclear pore
complex basket tip, in euchromatin, whereas inactive genes are
associated with lamin at the nuclear envelope, thereby coupling
nuclear architecture and gene regulation [18,27–30]. Using
three-dimensional immune-DNA ﬂuorescence in situ hybridiza-
tion and recurrent integrated genes, Marini et al. demonstrated
that HIV integrated preferentially in the nuclear periphery,
within 1 μmof the nuclear envelope (considering that on average
the cell diameter of CD4+ T cells is 7 μm). There transcription
was active, as shown by association with typical epigenetic marks
(H3K9ac, H3K36me3, H4K16ac, H4K20me). In contrast, pro-
viral insertions were disfavoured in lamin-associated domains,
containing inactive genes and located at the nuclear membrane,
as well as in the centre of the nucleus. These data further suggest
that chromatin located in the vicinity of the nuclear pore com-
plex is a major determinant of HIV integration site selection [26].
Once the viral intasome is within the nucleus and can access
the host chromatin, additional players further ﬁne tune ﬁnalof European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 324–332
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
FIG. 3. Mechanisms of integration site se-
lection. Integration site selection varies ac-
cording to the retrovirus and depends on
nuclear entry, chromatin organization, host
cell tethering proteins and viral integrase
(IN). Gag-encoded proteins are viral de-
terminants required for nuclear entry,
whereas the viral IN is required for the ﬁnal
stable insertion of the viral genome into
host chromatin. Human immunodeﬁciency
virus (HIV) pre-integration complex (PIC)
enters the nucleus through multiple in-
teractions with nuclear pore complex
components (green ovals) involving mostly
HIV capsid (CA) protein. Upon entry to the
nucleus, HIV PIC is close to gene-dense
regions that are located at the basket tip
of the nuclear pore complex, where are
located genes that are expressed (euchro-
matin). Lens-epithelium derived growth
factor (LEDGF)/p75 protein (orange oval)
then binds to HIV IN and to H3K36me3
histones that mark elongating transcription
units, guiding viral genome insertion in
active transcription units (red arrows in the
inset), with no bias for exons or introns if
normalized upon their respective lengths.
Murine leukemia virus (MLV) PIC enters the
nucleus during mitosis upon nuclear enve-
lope breakdown and binds ﬁrst to chro-
matin via p12 (not shown). Subsequently,
BET proteins bind to MLV IN, recruiting the
intasome to acetylated histone tails on the
chromatin (not shown), thereby guiding
MLV genome insertion in promoter and
enhancer regions (black arrows in the
inset).
328 Clinical Microbiology and Infection, Volume 22 Number 4, April 2016 CMIchromosomal preferences (Fig. 3). To date, LEDGF/p75 protein
(a splice variant product of PSIP1 gene) has been identiﬁed as
the major cellular tethering protein for HIV, recruiting the viral
integrase and further guiding HIV PIC along active transcription
units, to regions associated with epigenetic marks of gene
expression, including H3K36me3 [9,31–37]. Recently, cellular
proteins tethering MLV PIC to promoter and enhancer regions
associated with acetylated histone were identiﬁed as Bromo-
domain and Extraterminal domain (BET) proteins, including
Brd2, Brd3 and Brd4 [9,37–41]. Mutating the chromatin-
binding domain of these tethering proteins resulted in modi-
fying integration site preferences, further highlighting their roleClinical Microbiology and Infection © 2016 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licein driving ﬁne integration site selection [33,42–45]. Finally, the
viral integrase also affects the ﬁnal integration step, favouring
DNA sequences that are preferentially wrapped around nu-
cleosomes, facing outwards, and that are severely bent
[12,46–49].
In summary, PIC nuclear import and integration are tightly
coupled. HIV CA protein is required for nuclear import and dic-
tates integration in gene-dense regions that are located in the
nuclear pore periphery [12,50,51]. Once there, ﬁner chromo-
somal features for integration site selection aredictated by cellular
tethering proteins and the viral IN [9,12]. To date, LEDGF/p75 has
been shown to be the major protein guiding HIV PIC to activeEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 324–332
nses/by-nc-nd/4.0/)
CMI Ciufﬁ The beneﬁts of integration 329transcription units [7,8], whereas BET proteins are involved in
MLV PIC binding to promoter and enhancer regions [9].So What? Consequences for the Virus and
the HostThe stable insertion of the viral genome in the host chromatin
implies a life-long association of the virus with the infected cell,
which may have several implications for both the virus and the
host (Fig. 4).
To propagate, retroviruses need to replicate efﬁciently, i.e.
to infect/enter, to express and to release viral particle progeny.
The site of viral genome integration may impact viral propa-
gation as it may impact the level of viral gene expression (Fig. 4)
[52]. Integration in heterochromatin may repress viral
expression, and so inhibit particle production and spreading
infection. In contrast, integration in a very active chromatinPromoter/
Enhancer Exo
TSS
Promoter/
Enhancer
Proviral ge
Promoter/
Enhancer
TSS
Promoter/
Enhancer Exo
TSS
Promoter/
Enhancer
TSS
(a)
(b)
(c)
(d)
(e)
FIG. 4. Overview of consequences of viral
genome insertion in the host chromatin. (a)
Gene structure without viral genome
insertion. (b) Integration in intergenic re-
gions should have few consequences on
host cell gene expression, at least at the
structural level. However, integration in
regulatory elements (enhancers) could
disrupt their activity and so affect the level
of cellular gene expression. If these regions
are in heterochromatin, then proviral
genome expression will be reduced. (c)
Provirus is located within enhancer or
promoter region. This should result in efﬁ-
cient viral gene expression. The 30 long
terminal repeats may act as a strong pro-
moter driving higher expression level of the
downstream ﬂanking cellular gene
(increased black arrow). (d, e) Provirus is
located within the transcription unit, in the
antisense orientation (d) or in the same
orientation (e), and disrupts cellular gene
expression. Viral gene expression might be
impaired: (i) by collision of opposite tran-
scriptional machineries, (ii) by a stronger
cellular promoter or (iii) by viral gene out-
splicing. Aberrant cellular gene products can
arise due to truncations mediated by the
viral genome insertion or by chimeras with
viral genes. TSS: Transcription start sites.
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This is an open access artienvironment might result in viral gene over-expression that can
be toxic for the infected cell, thereby leading to its premature
death and a reduced release of infectious particles. The orien-
tation of viral integration with respect to the hosting gene can
also affect viral expression because RNA interference may
occur between viral transcription and cellular gene transcrip-
tion. In conclusion, there is a balance between integration site
location and viral gene expression, which in turn affects viral
particle production, and hence propagation.
Viral genome insertion in the host DNA, known as insertional
mutagenesis, also impacts the infected cell as it disrupts the host
genome integrity, with a more or less dramatic outcome (Fig. 4)
[53,54]. This latter depends on three parameters: (i) the nature
of the gene hosting or close to the integration event (i.e. genes
involved in cell proliferation, essential genes), (ii) the type of
gene structure modiﬁcation (i.e. dominant negative splice
variant, gene truncation) and (iii) the impact on gene expression
(i.e. over-expression or knock-down).Intron Intergenic regionn
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330 Clinical Microbiology and Infection, Volume 22 Number 4, April 2016 CMIThe type of gene affected by viral insertion will dictate the
outcome. Indeed it is easy to imagine that a cellular gene
involved in driving apoptosis, or in contrast in promoting cell
proliferation, eventually results in cell death or cancer. The
direct impact of integration site location on apoptosis has not
been thoroughly investigated because of the difﬁculty in
discriminating such cell death from viral gene-mediated toxicity.
In contrast multiple examples of leukaemia due to insertional
mutagenesis in the LIM-domain only 2 (LMO2) proto-oncogene
(and not due to virus-encoded oncogenes) have been identi-
ﬁed in gene therapy clinical trials using MLV-based vectors
(reviewed in [53,54]). Other genes over-expressed upon
insertional mutagenesis and resulting in clonal dominance or in
leukaemia include cyclin D2 (CCND2), MDS1 and EVI1 complex
locus (MECOM), PR domain containing 16 (PRDM16), SET binding
protein 1 (SETBP1), BMI1 proto-oncogene, polycomb ring ﬁnger
(BMI1) and High mobility group AT-hook 2 (HMGA2) [53]. In
some cases, insertional mutagenesis does not lead to cellular
transformation but provides a growth advantage (by promoting
cell proliferation or by promoting cell survival) ﬁnally resulting
in clonal expansion and dominance. This has been recently
exempliﬁed in antiretroviral therapy-suppressed HIV-positive
individuals, where most cells displayed the exact same proviral
insertion site within the same gene, such as BTB and CNC ho-
mology 1, basic leucine zipper transcription factor 2 (BACH2)
[55–57]. The mechanism by which such integration sites pro-
mote clonal dominance, i.e. through enhanced proliferation or
through enhanced survival, remains to be clariﬁed. These
studies would be helpful because they may impact the use of
safe viral vectors in gene therapy.
Finally, the stable integration of viral DNA in the host
genome may have further consequences for the infected host,
including long-term persistent infection and species evolution.
Indeed, in the case of HIV for example, infected cells can
harbour a silent provirus, i.e. in a state of transcriptional la-
tency, and so are not eliminated by the immune system [58].
These latently infected cells have a long half-life (memory CD4+
T cells with t1/2 ~44 months), thereby allowing the long-term
persistence of HIV within the infected organism. By mecha-
nisms that are not yet fully understood, latently infected
cells can be reactivated in vivo and then produce again viral
particles, re-kindling the infection. This long-term HIV persis-
tence is considered to represent the major obstacle for the
complete elimination of HIV, and thus for curing HIV. Integra-
tion therefore ensures a life-long stable association of the virus
with the infected host, representing a challenge for treatment
strategies.Clinical Microbiology and Infection © 2016 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceModern retroviruses currently challenging humans (HIV,
human T-lymphotropic virus) have a CD4 tropism, i.e. they
infect CD4+ cells, implying horizontal transmission between
hosts. In contrast, retroviruses able to infect germ-line cells,
and so stably inserting retroviral DNA sequences in the
genome of germ-line cells, would transmit the virus vertically,
to descendants, implying genetic inheritance. This process is
called endogenization of the retrovirus and may contribute to
shaping the human species. Although there is no such retro-
virus infecting humans currently, the human genome contains
multiple human endogenous retrovirus (HERV) sequences,
providing the proof-of-concept that such infections occurred in
the past (recently reviewed in [59,60]). These remnants of
ancient retroviral infections currently represent ~8% of the
human DNA genome [59]. More than 500 HERV families have
been identiﬁed, most of which have accumulated mutations and
are therefore defective to propagate infection [60,61]. How-
ever, some retroviral sequences, displaying different degrees of
evolution, are still active, thereby contributing to host life and
mammalian evolution. One prominent example of endogeni-
zation is syncytin [62]. Syncytin genes are derived from HERV-
encoded envelope genes (HERV-W, HERV-FRD), which have
fusogenic properties, and they are expressed in trophoblasts
and are essential for placenta morphogenesis in mammals.
Other examples also include the activity of HERV long terminal
repeat enhancer and promoter sequences in modulating or
driving expression of human genes, such as bile acid-CoA:amino
acid N-acyltransferase (BAAT), a liver-speciﬁc enzyme present
in bile and involved in lipid absorption [60]. Hence, retroviral
DNA sequences present in the host genome that survived
natural selection may offer beneﬁts to the infected host.
During the past decade, the impact of ERV expression in
human diseases has also been under scrutiny (reviewed in
[59,60,63]). These studies identiﬁed a role for ERV expression
in the development of some cancers, in neurological disorders
as well as in autoimmune disorders. Indeed expression of
HERV-encoded env (HERV-K, HERV-W, HERV-E) was shown
to be immunosuppressive and to promote cancer development,
including leukaemia, prostate cancer and breast cancer. Similar
correlation was identiﬁed between high expression levels of
HERV-W-encoded env and some neurological diseases,
including multiple sclerosis and schizophrenia [64]. HERV
expression can activate the innate immune response, thereby
leading to chronic inﬂammation and potentially contributing to
autoimmune diseases. Hence, deregulation of HERV expression
can be associated with human pathologies, using mechanisms
that will need to be further addressed and investigated.European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 324–332
nses/by-nc-nd/4.0/)
CMI Ciufﬁ The beneﬁts of integration 331ConclusionRetroviruses are fascinating organisms because they can be
detrimental to the infected host as well as providing beneﬁts,
shaping human evolution. They also provide fantastic tools and
opportunities to further understand human biology as well as
improve human health with gene therapy.
A better understanding of all the players involved in guiding
integration site selection and identifying the required de-
terminants for safe and targeted integration events are still
considered as the Holy Grail for gene therapy purposes. Simi-
larly, the advent of novel technologies in the last decade such as
high-throughput sequencing just started to unravel the impact
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